Why young HIV+ women won’t get powerful ARV soon positivelysharing 6 years ago Reading Time: < 1 minute WAR on HIV-Aids ARV drugs Image: FILE Young HIV-positive women will wait longer to access the powerful DTG antiviral drug. DTG (Dolutegravir) is the preferred first-line ARV in Kenya, but not recommended for women aged 15-49 because it can deform the spines of unborn babies. Read More
